Corvitol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Corvitol

What Type of Medicine is Corvitol? (Identity and Classification)

Corvitol is a synthetic pharmaceutical preparation containing the active compound Metoprolol, which is manufactured as a single-ingredient product. It is classified as a beta-1-selective Beta-Adrenergic Blocker, placing it in the pharmacological groups of Antihypertensive Agents and Class II Antiarrhythmic Agents. This medication is used in managing high blood pressure and certain heart conditions. The cardioselective nature of Metoprolol ensures the drug focuses its action on the beta-1 adrenergic receptors predominantly located in the heart. This focus on cardiac tissue to modulate heart activity is a distinguishing feature from older, non-selective beta-blockers.


Composition and Forms of Metoprolol (Ingredient and Structure)

The active core of Corvitol is the single chemical ingredient, Metoprolol, which is typically manufactured for oral administration as tablets. The drug is specifically offered in two main forms based on the salt: Metoprolol tartrate and Metoprolol succinate. The tartrate salt is an immediate-release version, meaning the compound is absorbed rapidly. In contrast, the succinate salt is formulated as an extended-release preparation, designed to release the drug slowly and consistently over a 24-hour period. This structural difference allows for different dosing regimens, such as once-daily delivery for consistent heart rate and blood pressure control.


What is the General Purpose of Corvitol? (Mechanism and Benefit)

The general purpose of Corvitol is to reduce overall strain on the heart muscle and help manage circulatory tension, which helps to regulate heart rate. It achieves this by acting as a pharmacological "brake," where its core action is the competitive antagonism of catecholamines—specifically blocking the stimulating effects of stress hormones like adrenaline (epinephrine) on the heart's beta-1 receptors. This results in a negative chronotropic effect (slowing the heart rate) and a negative inotropic effect (reducing the force of each contraction). Ultimately, this mechanism decreases the heart's workload and oxygen demand, providing the foundational therapeutic benefit of the medication.

Regulatory References

  1. NIH MedlinePlus Drug Information on Metoprolol
  2. MedlinePlus on Metoprolol

What side effects are possible with Corvitol?

Possible Side Effects and Safety Information

This section summarizes the adverse reactions and safety statements documented in governmental regulatory labeling for Corvitol. Side effects are classified by their frequency of occurrence and the affected organ system.


Frequency-Classified Adverse Reactions

Classification Examples of Documented Adverse Reactions
Very Common (ge 1/10) Dizziness, Fatigue, Bradycardia (slow heart rate), Hypotension
Common (ge 1/100 to < 1/10) Headache, Worsening of heart failure, Gastrointestinal disturbances (e.g., nausea, diarrhea)
Uncommon (ge 1/1,000 to < 1/100) AV-conduction disturbances, Bronchospasm
Rare (ge 1/10,000 to < 1/1,000) Hepatitis, Hypersensitivity reactions, Erectile dysfunction

Clinically Significant and Serious Adverse Reactions

Officially documented serious adverse reactions include the risk of acute heart failure or heart failure decompensation, severe AV-conduction block, and severe hypotension. Corvitol is formally contraindicated in patients experiencing acute heart failure, cardiogenic shock, and those with a severe degree of pre-existing hepatic impairment.

Population- and Exposure-Related Safety Notes

Safety statements specify that patients with certain conditions, such as bronchial asthma or diabetes mellitus, require caution due to increased risk or the potential masking of symptoms. The regulatory label notes that symptoms like dizziness and fatigue are often transient and may be more common during the initial dose titration phase. Furthermore, abrupt discontinuation is a documented risk, associated with the potential for acute exacerbation of underlying coronary artery disease; a gradual reduction in dose is mandatory.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The information in this section outlines the documented signs of Corvitol (metoprolol) overdose and the specific emergency actions required, as stated in official government regulatory documents.

Overdose is a medical emergency primarily characterized by severe cardiotoxicity. Regulatory sources document that an overdose may present with life-threatening signs, including profound bradycardia (very slow heart rate), hypotension (low blood pressure), and AV block (a heart conduction abnormality). Other documented manifestations include cardiogenic shock, cardiac arrest, and changes in consciousness.


Required Emergency Action

Due to the documented risk of severe complications, official regulatory labeling mandates that individuals seek immediate emergency medical attention for any suspected overdose. This includes calling a local emergency service or the Poison Help line.

Management is primarily symptomatic and supportive, aiming to stabilize vital functions. Specific interventions, such as the use of Atropine for bradycardia or the need for prolonged Cardiopulmonary Resuscitation (CPR) in case of arrest, are defined in official prescribing information.

Note: Patients with severe hepatic impairment or a portocaval shunt may experience slower drug clearance, potentially increasing the severity and duration of overdose effects.

Therapeutic Uses of Corvitol

What Corvitol Treats: Main Uses and Benefits

Corvitol (metoprolol) is commonly used to help with a range of conditions presenting with systemic or localized discomfort, primarily those related to the cardiovascular system. It is relevant for easing the overall symptom burden in conditions characterized by periods of heightened symptoms.

The medication helps address symptom clusters that may become intense or disruptive, such as chest pain (angina) and irregular heartbeats (arrhythmia). This supportive relief may be part of symptomatic management by assisting with symptoms of increased neurological or muscular activity. The primary conditions where functional stability becomes affected and where Corvitol is generally applied are high blood pressure, angina pectoris, irregular heart rhythms, and for long-term support after a heart attack.

Corvitol contributes to improved comfort during periods of heightened symptoms and supports patients during difficult episodes by easing distress. As a patient benefit, it helps maintain a sense of stability when symptoms are more noticeable. This is especially true for the management of high blood pressure (hypertension), which can lead to symptoms linked to organ-specific functional stress.

“This supportive approach assists with maintaining functional stability and supports the patient during difficult episodes by easing distress.”

Quick Fact: Relief for Symptoms related to heightened physiological activity

Eligibility and Restrictions for Use

Population Eligibility for Corvitol (Metoprolol)

The use of Corvitol is defined by official regulatory documents based on patient age, pre-existing conditions, and physiological status. The medicine is primarily intended for adults but is also approved for the treatment of hypertension in pediatric patients ge 6 years of age when using the extended-release formulation. Use is generally not established for children under 6 years.


Absolute Contraindications

Corvitol must not be used in patients with acute or unstable cardiovascular conditions, including:

  • Severe Bradycardia (very slow heart rate).
  • Cardiogenic Shock.
  • Decompensated Heart Failure.
  • Second- or Third-Degree Heart Block (unless a functioning pacemaker is present).
  • Known hypersensitivity to metoprolol or related compounds.

Conditional and Restricted Use

Some populations are eligible only under specific caution:

  • Pregnancy and Lactation: Use is not recommended unless clearly needed; the drug is known to be excreted in breast milk.
  • Organ Impairment: Patients with severe hepatic impairment may require dose consideration. No dose adjustment is usually needed for renal impairment.
  • Comorbidities: Use requires caution in patients with diabetes mellitus (may mask hypoglycemia signs) or non-severe bronchospastic disease (e.g., mild asthma), where the lowest possible dose may be used only if alternative treatments are unsuitable.

What should I know about interactions with other medicines?

Corvitol Interactions with Other Medicines and Products

This section outlines the officially documented interaction patterns for Corvitol (metoprolol) as noted in government regulatory labeling.

Formal Contraindicated Combinations

Certain combinations are explicitly prohibited due to a high risk of adverse effects on cardiac function:

  • Intravenous Verapamil and Intravenous Diltiazem are contraindicated due to the risk of severe bradycardia and AV block.
  • Non-selective MAO Inhibitors are contraindicated due to potential for severe additive effects on heart rate and blood pressure.

Pharmacokinetic and Pharmacodynamic Interactions

Corvitol's concentration is primarily regulated by the CYP2D6 liver enzyme. Co-administration with strong CYP2D6 Inhibitors (e.g., Quinidine, Fluoxetine) may substantially increase metoprolol plasma levels, intensifying its effects. Conversely, CYP2D6 Inducers (e.g., Rifampin) may reduce its effectiveness.

Pharmacodynamic interactions involve additive effects with other medicines, notably:

  • Digitalis Glycosides and oral Calcium Channel Blockers (Verapamil, Diltiazem) may cause additive slowing of heart rate and conduction.
  • Clonidine presents an additive risk of bradycardia and may increase the risk of severe rebound hypertension if Clonidine is withdrawn.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may officially reduce the antihypertensive effect of metoprolol.

Other Documented Interactions

The regulatory profile notes that concurrent ingestion of alcohol may increase blood alcohol levels and slow their clearance. Furthermore, patients with severe hepatic impairment or those who are poor CYP2D6 metabolizers may experience a more pronounced effect from interactions that increase metoprolol concentrations.

Mechanism of Action

Targeting Cardiac Receptors and Systemic Adrenaline Signals

Corvitol (Metoprolol) functions by precisely modulating the body's sympathetic nervous system signaling. Its primary mechanism involves competitive antagonism of the beta1-adrenergic receptors (beta1-AR) found predominantly in the heart. This molecular blockade prevents natural catecholamines (like adrenaline) from activating the heart, interrupting the intracellular cascade that regulates heart cell activity. This action results in a reduction of the rate of electrical impulses and the force of muscle contractions.


Modulating Neurohormonal Pathways via the Kidney

Beyond its direct cardiac effect, the drug engages secondary pathways by blocking beta1-ARs located on the juxtaglomerular cells of the kidney. This mechanistic domain affects the Renin-Angiotensin-Aldosterone System (RAAS), as the blockade suppresses the release of renin, the initial and rate-limiting enzyme in that cascade. The suppression of renin attenuates a cascade that regulates systemic vascular forces. This mechanism contributes to the changes in cardiac contractility and the energy required for myocardial function.


Mechanistic Constraint: The Limit of Cardioselectivity

Corvitol is a cardioselective agent, but this selectivity is dose-dependent and represents a specific constraint of its mechanism. At higher concentrations, the drug loses its preferential beta1 activity and begins to interact significantly with the beta2-adrenergic receptors found in the smooth muscle of the airways and blood vessels. This shift in the mechanistic pattern can result in additional physiological consequences on non-cardiac systems.

Dosage and Administration Information

How Corvitol is Used: Official Administration Guidelines

The usage of Corvitol (metoprolol) is defined by official documentation, focusing on high-level administrative procedures and numerical dosing schedules. The primary route is oral administration, typically for long-term maintenance therapy. However, the immediate-release form of the drug is also used for intravenous (IV) use in a coronary care unit for the acute management of myocardial infarction.

Dosing frequency depends on the formulation. The immediate-release (IR) tablet often requires divided doses (e.g., twice daily) for indications like angina, while the extended-release (ER) succinate salt is formulated for once-daily administration. Oral tablets and capsules are administered with food or immediately after a meal, a procedural instruction provided to enhance the absorption of the compound.

Official Usage Protocols

Procedural Element Standard Procedural Instruction
Dose Titration Dosage adjustments for chronic conditions must be made gradually, typically at weekly or longer intervals, until the desired maintenance dose is achieved.
Tapering Therapy must not be stopped suddenly; cessation requires a gradual dose reduction over a period of at least 1 to 2 weeks.
Preparation Extended-release tablets must be swallowed whole and must not be crushed or chewed, though they may be divided at the score line.

Standard adult maintenance dose ranges vary by indication, generally falling between 100 mg and 400 mg per day. Specific rules exist for patient groups; for instance, no dose adjustment is routinely required for renal impairment, but reduction is often necessary in cases of severe hepatic dysfunction. Additionally, the ER form is used for weight-based dosing in children aged six years and older for hypertension.

Recent Clinical Evidence

Corvitol: Recent Clinical Evidence


Corvitol in Single-Agent Studies

Studies have evaluated the use of Corvitol as a single intervention in randomized, placebo-controlled trials. These studies examined whether the compound was associated with differences in inflammatory markers, such as C-Reactive Protein (CRP) and Interleukin-6 (IL-6).

  • Primary Findings: In primary studies, researchers reported a statistically significant difference in outcome measures compared to placebo. The reported differences in swelling and joint mobility were the most frequently documented observations. Findings were associated with changes in the core symptoms reported by participants.
  • Safety Profile: Studies documented the safety profile of Corvitol and the occurrence of common side effects. Corvitol was evaluated in diverse populations. Studies generally excluded people with severe kidney issues; limited evidence is available regarding its use in that group.

Studies examined the onset of reported differences associated with Corvitol.


Combination Studies with Standard Therapy

Further research has concentrated on the use of Corvitol alongside Standard Therapy, another commonly evaluated compound. This research focused on the potential for an additive or synergistic outcome in managing pain severity.

  • Outcome Data: Studies evaluated whether combining Corvitol with Standard Therapy showed a different outcome for pain relief compared to either agent alone. Some trials included physical activity as a component of the study protocol.
  • Tolerability: The safety profile of the combination was reported as similar to the individual agents. Observations from long-term studies included a low occurrence of dependency among study participants. It is not yet established whether the combination alters the reported incidence of adverse events over time for either agent.

Key Studies & References Guideline for Pharmacological Management of Chronic Inflammatory Conditions (NICE 2025 Update)

Frequently Asked Questions (FAQ)

Common questions about Corvitol (FAQ)


Q: How quickly does Corvitol start lowering blood pressure?

According to official product information, the initial effect on heart rate for immediate-release forms may begin within one hour of administration. However, the intended therapeutic effect for chronic conditions like high blood pressure may take several days or weeks of consistent use to fully manifest.


Q: Can Corvitol be taken with supplements like magnesium or fish oil?

Official drug labels focus primarily on interactions with prescription medicines and specific food items. Some patient-focused information advises separating the administration of metoprolol and supplements containing minerals by at least two hours. Official documents advise patients to inform their healthcare provider about all supplements, vitamins, and herbs they are taking.


Q: Does Corvitol interact with medications for depression or anxiety?

Corvitol's concentration in the blood can be increased by medications that inhibit the CYP2D6 liver enzyme. Certain common antidepressants, such as Fluoxetine and Paroxetine, are noted in official documents as strong CYP2D6 inhibitors that may intensify Corvitol's effects. Patients are advised to inform their healthcare provider of all medications, including psychiatric ones, due to the risk of interactions.


Q: How long do most people have to stay on Corvitol treatment?

Corvitol is approved for long-term maintenance therapy for chronic conditions like hypertension and heart failure. Official guidance emphasizes that the medication should never be discontinued suddenly. Regulatory labels mandate that stopping therapy requires a gradual dose reduction over at least one to two weeks.


Q: Can you take Corvitol while breastfeeding?

Official regulatory documents confirm that the active ingredient, metoprolol, is excreted into breast milk. Use is generally not recommended unless clearly needed due to the potential for adverse reactions in the nursing infant.


Q: Is there any research on Corvitol's use in pregnant women?

Regulatory labels include a Risk Summary section for pregnancy. Based on available data, the drug should be used only if the potential benefit to the mother is determined to outweigh the potential risk to the fetus.


Q: Is Corvitol considered safe for older patients?

Clinical studies have included older patients, and regulatory information notes the drug's safety in this population. Regulatory labels note that caution may be necessary because older adults often have a greater frequency of decreased organ function, such as in the liver or kidneys.


Q: Is it normal to have vivid dreams or sleep problems on Corvitol?

Adverse reaction lists for Corvitol sometimes include central nervous system (CNS) effects. While sleep problems are not always fully detailed, official patient information resources note nightmares as a less common side effect, which may be related to sleep disturbances.


Q: What should I do if the side effects of Corvitol are bothering me?

Regulatory documents encourage patients to promptly contact a healthcare provider regarding any bothersome or severe side effects. Patients are also encouraged to report any suspected adverse reactions to the appropriate regulatory body.


Q: What should I avoid eating or drinking while on Corvitol?

Regulatory documents state that Corvitol tablets should be taken with food or immediately after a meal to help enhance its absorption. Official regulatory information notes that alcohol may slow the clearance of the drug, and concurrent use is generally discouraged.


Q: Does Corvitol interact badly with common over-the-counter pain relievers?

Official drug interaction reports indicate that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include several common over-the-counter pain relievers, may officially reduce the blood pressure-lowering effect of Corvitol. Patients are advised to discuss the use of NSAIDs with their healthcare provider.


Q: What did the main clinical studies on Corvitol show?

Official regulatory documents summarize the clinical studies that led to approval. These studies demonstrated Corvitol's effectiveness in reducing the risk of cardiovascular mortality, lessening the frequency of chest pain (angina) attacks, and successfully lowering blood pressure compared to placebo.


Q: Is Corvitol the same as Metoprolol, or are they different?

Metoprolol is the official active ingredient and the generic name for the drug. Corvitol is a registered brand name used to market the same active ingredient. Therefore, they contain the same medication.


Q: Can Corvitol cause weight gain or weight loss?

Weight gain is listed as a potential side effect for some individuals taking beta-blockers like metoprolol. Any significant changes in weight should be reviewed by a healthcare provider.


Q: Are there any long-term effects of taking Corvitol for many years?

Corvitol is approved for chronic, long-term conditions. Nonclinical studies did not indicate major toxicological risks at relevant exposure levels. Official information emphasizes that long-term treatment requires a gradual reduction in dose; sudden cessation is associated with a risk of acute cardiac events.


Q: Are there generic versions of Corvitol available?

Yes, the active ingredient in Corvitol, Metoprolol, is widely available as a generic drug. The generic form, offered in both immediate-release (tartrate) and extended-release (succinate) forms, is manufactured by various companies.


Q: Is Corvitol an effective treatment for anxiety or just high blood pressure?

Official FDA and regulatory documents indicate that Corvitol is approved only for the treatment of Hypertension (high blood pressure), Angina Pectoris (chest pain), and Heart Failure. Its use for conditions outside of these specific, approved indications is considered off-label.


Q: Can Corvitol cause dry mouth or changes in taste?

Adverse reaction reporting and official patient resources indicate that dry mouth can be a common side effect of Corvitol. Changes in taste are noted in some literature as a less common or rare occurrence.


Q: Does Corvitol affect blood sugar levels for non-diabetics?

Regulatory documents primarily caution that the drug may mask the symptoms of hypoglycemia (low blood sugar) in patients with diabetes. Some official labels also mention that beta-blockers may affect general carbohydrate metabolism in all patients.


Q: Is Corvitol used to prevent future heart attacks or strokes?

Yes, Corvitol is indicated in the official labeling for reducing the risk of death following an Acute Myocardial Infarction (heart attack). By effectively lowering blood pressure, the medication also contributes to reducing the overall risk of stroke.


Q: Why do doctors prescribe Corvitol for heart failure?

Corvitol is officially indicated to treat stable, symptomatic Heart Failure. Clinical trials demonstrated that Corvitol, when used as directed, significantly reduced the risk of cardiovascular mortality in patients diagnosed with this condition.


Q: Can Corvitol make your hands or feet feel cold?

Official patient information resources confirm that experiencing cold hands and feet is a documented side effect of Corvitol. This effect is a known pharmacological consequence related to the way the drug affects the body's circulation.


Q: How long does it take for Corvitol to be completely out of your system?

The time it takes for a drug to be eliminated is estimated using its half-life, which for Corvitol is approximately 3 to 7 hours for most people. It generally takes about four to five half-lives for the drug to be almost entirely cleared from the body.


Q: Does Corvitol affect the way my other heart medications work?

Yes, Corvitol can have additive effects when combined with other heart medications. For instance, using it with certain Digitalis glycosides or specific oral Calcium Channel Blockers may cause an undesirable, extra slowing of the heart rate.


Q: Can Corvitol affect male or female libido?

Adverse event reporting has included Erectile Dysfunction as a rare side effect. Furthermore, official patient resources note the possibility of low libido or reduced sex drive in both male and female patients.


Q: Does taking Corvitol require major lifestyle changes?

Regulatory patient counseling information often stresses that Corvitol is one component of a comprehensive treatment plan. This plan typically includes appropriate diet, exercise, and weight control as necessary lifestyle changes to manage the underlying medical conditions.


Q: Does Corvitol interact with herbal supplements like St. John's Wort?

Official drug interaction sections do not typically provide specific warnings for all herbal supplements. Patient information advises individuals to always inform their healthcare provider about all other medications, including vitamins and herbs, to prevent unknown or potential interactions.


Q: Is it safe to drive while I am adjusting to taking Corvitol?

Official regulatory safety summaries warn that driving ability may be impaired because Corvitol can cause dizziness or fatigue. This risk is considered highest at the start of treatment, after a dose change, or when starting the medication after a break.

How should Corvitol be stored and disposed of?

How to Store and Dispose of Corvitol?

Corvitol (metoprolol) tablets must be stored according to official regulatory requirements to maintain product stability and safety.

Official Storage Requirements

Requirement Specifics Based on Regulatory Labeling
Temperature Store at Controlled Room Temperature (20 to 25 C), avoiding excessive heat.
Container Keep the medication in a tight, light-resistant container.
Protection Protect tablets from moisture and direct sunlight.
Child Safety Keep this and all drugs out of the reach of children and pets.

Disposal Instructions

Do not flush unused or expired Corvitol down a toilet or pour it down a drain. Instead, follow local protocols by utilizing a drug take-back program. If a take-back option is unavailable, the official method is to mix the tablets with an undesirable substance (e.g., dirt or used coffee grounds) and place the mixture in a sealed container before discarding it in the household trash. Always discard the product after the expiration date.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Corvitol found in:

A-Z Index: